Welcome to our dedicated page for International Flavors&Fragranc news (Ticker: IFF), a resource for investors and traders seeking the latest updates and insights on International Flavors&Fragranc stock.
International Flavors & Fragrances Inc. (IFF) (NYSE: IFF) generates a steady flow of news that reflects its role as a global leader in flavors, fragrances, food ingredients, health and biosciences. This news page aggregates company announcements, press releases and related coverage so readers can follow how IFF’s strategies, operations and governance evolve over time.
IFF’s news often highlights developments across its core segments—Taste, Health & Biosciences, Scent and Food Ingredients. Examples include updates on segment performance from quarterly earnings releases, commentary on market dynamics within these segments and information on productivity and margin initiatives. Investors and analysts can use these items to understand how the company’s segment-level trends contribute to overall performance.
Operational and technology-focused announcements are another key news category for IFF. Recent releases describe the implementation of the Colibri smart dosing robot at its Scent and Taste production plant in Chin Bee, Singapore, which is used to produce fragrance sample batches on demand, and the installation of a green hydrogen production facility at its Benicarló, Spain site to support sustainable fragrance ingredient manufacturing. News items also cover plans for new facilities, such as a scent creative center in Mumbai, India, designed to enhance fragrance innovation in that market.
Corporate governance, capital allocation and strategic partnerships feature prominently in IFF’s news flow. The company reports on board appointments, changes in committee assignments and amendments to its bylaws. It also announces dividends, share repurchase authorizations and collaborations, such as its strategic collaboration with BASF to develop next-generation enzyme technologies and biobased polymers. Bookmark this page to access a consolidated view of IFF’s latest publicly released information, from financial results to sustainability initiatives and board-level decisions.
IFF (NYSE: IFF) announced the consolidation of its Mexico operations at a new site in Mexico City's Tecnoparque business complex. The relocation will start with the Global Business Services Center and is expected to complete by 2026. The new facility will accommodate up to 650 employees across Health & Biosciences, Scent, Taste, and Food Ingredients divisions.
The strategic move includes laboratories for product creation, testing, R&D, and business services. The Tecnoparque complex features 50,000 square meters of green space, solar power generation, and advanced water management systems. IFF's existing Tlalnepantla facilities will continue operating as a strategic production site for Scent and Taste business units.
IFF (NYSE: IFF) has unveiled its new Citrus Innovation Center in Lakeland, Florida, in partnership with Florida Polytechnic University. The 30,000 square foot facility features state-of-the-art capabilities in botanical research, processing, analytics, and product creation for scent and taste applications.
The center includes advanced technologies like a 360-degree digital immersion room and focuses on applications in food and beverage, fine fragrance, body care, and fabric & home care. Supporting approximately 40 jobs, the facility emphasizes sustainability with LEED silver certification and a solar array system meeting its entire power demand.
The center demonstrates IFF's commitment to innovation and external partnerships, offering customers rapid product development capabilities, innovative citrus applications, and advanced product testing. Located on Florida Polytechnic University's campus, the facility provides direct access to industry experts and academia while featuring on-site prototyping capabilities for customized solutions.
IFF Pharma Solutions has launched Low Nitrite METHOCEL™ HPMC, a specialized range of cellulose ethers designed to reduce nitrosamine formation risk in pharmaceutical dosages. The innovative product maintains nitrite levels at or below 200 parts per billion, verified through validated 2D ion chromatography with mass spectrometry testing for each batch.
The new product line offers the same reliability and performance as standard METHOCEL™ while addressing industry concerns about nitrosamine risk mitigation. Through enhanced process controls and analytical science, the company ensures minimal nitrite content, making it suitable for applications where low nitrite levels are crucial.
Every batch receives a nitrite test result on the certificate of analysis, demonstrating IFF's commitment to quality and safety standards in pharmaceutical manufacturing.
IFF (NYSE: IFF) has launched its Science of Performance program, a new scientific approach to fragrance creation that enhances scent design efficiency and precision. The program combines decades of measured data with proprietary AI capabilities and advanced expertise across various applications.
The initiative focuses on three key scientific tracks: Fragrance Engineering using AI-driven consumer insights, Sustainable Fragrance Delivery Systems exploring technologies like fragrance encapsulation, and Additive Materials for enhancing scent profiles. These tracks power two platforms: IFF SCENT+ for optimizing fragrance intensity and IFF CTRL+D™ for malodor control.
IFF (NYSE:IFF) and Kemira have announced the formation of Alpha Bio, a joint venture focused on commercial-scale production of renewable biobased materials. The venture involves a €130 million investment, with production scheduled to begin in late 2027 at IFF's biorefinery in Kotka, Finland.
The facility will convert up to 44,000 MT of plant sugars into bioproducts, including high-performance biopolymers for home and personal care and industrial applications. The production will utilize IFF's proprietary Designed Enzymatic Biomaterial™ (DEB) platform technology, which creates biobased materials using plant-based sugars and enzymes under mild process conditions.
The joint venture will operate independently and is expected to create approximately 30 direct new jobs in the Kotka area, with additional employment during construction. The facility will manufacture specific DEB technology-enabled products exclusively for IFF and Kemira's use.
IFF (NYSE:IFF) Pharma Solutions will showcase its innovative excipient technologies at CPHI Japan 2025, taking place April 9-11 at Tokyo Big Sight. The company will highlight three key product lines:
1. Oral Disintegrating Tablet (ODT) Solutions, featuring Ac-Di-Sol® super disintegrant for rapid dissolution
2. Controlled Release Portfolio, including METHOCEL™ HPMC, ETHOCEL™ Ethylcellulose for water-resistant coatings, and POLYOX™ Polyethylene Oxide for high-swell matrices
3. Low-Nitrite Solutions, including Avicel® PH LN and Low Nitrite METHOCEL™, designed to reduce nitrosamine formation risks in oral solid dosages and meet Japan's regulatory standards
IFF (NYSE:IFF) has announced the expansion of its Enviva® PRO three-strain Bacillus probiotic product line to include swine applications. The product, previously successful in broiler production, aims to address health challenges in weaned piglets.
Studies conducted by IFF demonstrated significant benefits, including a 2.5% improvement in average daily weight gain and a 6.3% reduction in diarrhea frequency compared to control groups. The probiotic helps establish optimal gut health and improves nutrient digestion during the critical post-weaning period when piglets face nutritional stress and digestive health challenges.
The product is currently available to swine producers in Japan and the US, with plans for expansion to other markets pending regulatory approvals.
IFF (NYSE: IFF) has announced its Board of Directors' declaration of a regular quarterly cash dividend of $0.40 per share for the first quarter of 2025. The dividend will be payable on April 11, 2025 to shareholders of record as of March 21, 2025.
IFF, the global leader in flavors, fragrances, food ingredients, health and biosciences, continues its commitment to delivering sustainable innovations for everyday products focused on wellness, sensory experiences, and human experience enhancement.
IFF (NYSE: IFF) has announced a $70 million expansion of its Cedar Rapids, Iowa facility, adding 47,000 square feet to produce high-quality fruit-based ingredients for the healthy snacks market. This expansion aims to create up to 40 new jobs and will be operational by the latter half of 2026. The facility will feature advanced technologies, high automation, and sustainable practices, including efficient heat recovery systems and minimized energy and water consumption.
The Cedar Rapids plant will be the first U.S. facility to produce TAURA by IFF ingredients, known for their clean-label fruit and vegetable pieces and pastes. These ingredients, already produced in Belgium and New Zealand, will enhance products like snacks, chocolates, cereals, and bakery items. The expansion will also improve supply chain efficiencies due to its proximity to U.S. customers.
Andy Muller, President of Food Ingredients, emphasized the competitive edge this expansion will provide in the healthy snacks sector, leveraging over three decades of proprietary technology. The existing Cedar Rapids plant, which currently produces enzymes for various industries, has seen substantial enhancements in recent years and employs over 200 workers.
IFF (NYSE: IFF) announced key changes to its executive leadership team. Simon Herriott, president of Health and Biosciences, will step down after 21 years of service. Leticia Gonçalves, former ADM's president of precision fermentation, will succeed him effective March 1.
The company also welcomed Andy Muller as president of Food Ingredients, who joined in December 2024 from Corbion. Yuvraj Arora has taken on the role of President, Taste and Chief Commercial Officer, while Ana Paula Mendonça (President, Scent) and Angela Strzelecki (President, Pharma Solutions) maintain their current positions.
These changes align with IFF's external reporting structure, reflecting the company's focus on strengthening its leadership across key divisions including Health & Biosciences, Food Ingredients, Taste, Scent, and Pharma Solutions.